Different subsets of γδ T cells display differential expression of immune checkpoint receptors (ICRs) and have distinct ...

Ike Onwere, MD: It is [sometimes] based on giving the FOLFOX [leucovorin, fluorouracil, and oxaliplatin] every 2 weeks. It’s ...

While this panel has grown in recent years, many experts believe additional biomarkers should also be incorporated as ...

Imfinzi is the first immunotherapy approved for perioperative use to treat gastric and gastroesophageal junction cancers.

The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential ...

In a Nov. 21 note, he maintained a “Speculative Buy” rating and C$5.25 (US$4.00) target.

The firm plans to submit results from the Phase III OptiTROP-Lung05 trial to regulators in China, seeking approval for sac-TMT and Keytruda in PD-L1-positive patients.

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a ...